Company profile
Fulgent Genetics, Inc.
NASDAQ:FLGTMedical Specialities
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06332092 | phase2 | active_not_recruiting | 2024-04-10 | 2025-12-31 | Fulgent Pharma LLC. | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma |
| NCT06694480 | phase1 | recruiting | 2025-07-03 | 2027-12-31 | Fulgent Pharma LLC. | Study of FID-022 in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.